SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(Österborg Anders) "

Sökning: WFRF:(Österborg Anders)

  • Resultat 41-43 av 43
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
41.
  • Sylvan, Sandra Eketorp, et al. (författare)
  • First-line therapy in chronic lymphocytic leukemia : a Swedish nation-wide real-world study on 1053 consecutive patients treated between 2007 and 2013
  • 2019
  • Ingår i: Haematologica. - : FERRATA STORTI FOUNDATION. - 0390-6078 .- 1592-8721. ; 104:4, s. 797-805
  • Tidskriftsartikel (refereegranskat)abstract
    • The aim of this study was to investigate long-term outcome following first-line therapy in consecutive chronic lymphocytic leukemia (CLL) patients in a well-defined geographic area: Sweden. All patients diagnosed with CLL (2007-2013) (n=3672) were identified from national registries, screening of patient files identified all (100%) treated first line (n=1053) and for those, an in-depth analysis was performed. End points were overall response rate, progression-free survival (PFS), overall survival (OS), and safety. Median age was 71 years; 53% had Rai stage III-IV and 97% had performance status grade 0-2. Fluorescence in situ hybridization (FISH) was performed in 57% of patients: 15% had del(17p). Chlorambucil + prednisone was used in 39% (5% also received rituximab). Fludarabine+cyclophosphamide+rituximab or fludarabine+cyclophosphamide was used in 43% and bendamustine + rituximab in 6%. Overall response rate was 64%; chlorambucil 43%, fludarabine+cyclophosphamide+rituximab 84%, fludarabine+cyclophosphamide 75% and bendamustine + rituximab 75%. Median PFS and OS was 24 and 58 months, respectively, both were significantly associated (multivariate analysis) with type of treatment, del(17p), performance status, gender, age and geographical region (OS only). Chlorambucil-treated patients had a median PFS and OS of only 9 and 33 months, respectively. Chlorambucil usage declined gradually throughout the study period, but one-third of patients still received chlorambucil + rituximab in 2013. Infections >= grade III were significantly associated with treatment; chlorambucil 19% versus fludarabine+cyclophosphamide+rituximab 30%. Richter transformation occurred in 5.5% of the patients, equally distributed across therapies. This is the largest retrospective, real-world cohort of consecutive first-line treated CLL patients with a complete follow up. In elderly patients, an unmet need for more effective, well-tolerated therapies was identified.
  •  
42.
  • van Vollenhoven, Ronald F., et al. (författare)
  • Biopsy-verified response of severe lupus nephritis to treatment with rituximab (anti-CD20 monoclonal antibody) plus cyclophosphamide after biopsy-documented failure to respond to cyclophosphamide alone
  • 2004
  • Ingår i: Scandinavian Journal of Rheumatology. - : Taylor & Francis. - 0300-9742 .- 1502-7732. ; 33:6, s. 423-427
  • Tidskriftsartikel (refereegranskat)abstract
    • BACKGROUND: The monoclonal anti-B cell antibody rituximab (Rituxin, Mabthera) may be of benefit in antibody-driven diseases, including systemic lupus erythematosus (SLE) nephritis.PATIENTS AND TREATMENT: Two female patients with biopsy-confirmed severe and active SLE nephritis despite treatment with cyclophosphamide (CyX) were given four rituximab infusions plus two additional CyX infusions.RESULTS: Both patients tolerated the treatment well and SLE activity improved. On repeat kidney biopsy after the combined treatment, Patient 1 showed a profound reduction of nephritis activity, and she was maintained on low-dose prednisolone only. A repeat biopsy after 1 year confirmed the sustained reduction of lupus nephritis activity. In Patient 2, rebiopsy after combined treatment also showed a significant reduction in disease activity.CONCLUSION: These cases provide histopathological documentation of a significant treatment benefit from rituximab plus CyX in two patients refractory to CyX alone. This combination is being explored further as salvage therapy for such CyX-resistant patients.
  •  
43.
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 41-43 av 43
Typ av publikation
tidskriftsartikel (37)
annan publikation (4)
doktorsavhandling (1)
forskningsöversikt (1)
Typ av innehåll
refereegranskat (37)
övrigt vetenskapligt/konstnärligt (6)
Författare/redaktör
Österborg, Anders (43)
Hansson, Lotta (14)
Jernberg-Wiklund, He ... (12)
Nilsson, Kenneth (11)
Nowak, Piotr (7)
Ljungman, Per (7)
visa fler...
Strömberg, Thomas (7)
Bergman, Peter (7)
Aleman, Soo (7)
Chen, Puran (7)
Ljunggren, Hans-Gust ... (7)
Buggert, Marcus (7)
Blennow, Ola (7)
Mielke, Stephan (7)
Söderdahl, Gunnar (7)
Smith, C. I. Edvard (7)
Akber, Mira (7)
Carlson, Kristina (5)
Öberg, Fredrik (5)
Bogdanovic, Gordana (5)
Vesterbacka, Jan (5)
Muschiol, Sandra (5)
Agarwal, Prasoon (4)
Kalushkova, Antonia (4)
Wullimann, David (4)
Gao, Yu (4)
Hammarberg, Anna (4)
Hojjat-Farsangi, Moh ... (4)
Rosenquist, Richard (3)
Okrój, Marcin (3)
Healy, Katie (3)
Dimberg, Anna (3)
Birgegård, Gunnar, 1 ... (2)
Gascon, Pere (2)
Hedenus, Michael (2)
Nilsson, Peter (2)
Kokhaei, Parviz (2)
Hagberg, Hans (2)
Hober, Sophia, Profe ... (2)
Enroth, Stefan (2)
Alzrigat, Mohammad (2)
Párraga, Alba Atienz ... (2)
Ma, Anqi (2)
Jin, Jian (2)
Stamatopoulos, Kosta ... (2)
Ghia, Paolo (2)
Johansson, Hemming (2)
Blom, Anna M. (2)
Axelsson, Per (2)
Palma, Marzia (2)
visa färre...
Lärosäte
Karolinska Institutet (35)
Uppsala universitet (24)
Umeå universitet (9)
Lunds universitet (8)
Kungliga Tekniska Högskolan (3)
Linköpings universitet (3)
visa fler...
Örebro universitet (2)
visa färre...
Språk
Engelska (39)
Odefinierat språk (4)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (25)

År

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy